Barinthus Biotherapeutics’ (BRNS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Barinthus Biotherapeutics (NASDAQ:BRNS) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $3.00 target price on the stock.

Barinthus Biotherapeutics Trading Down 2.0 %

Shares of BRNS opened at $0.99 on Friday. The firm has a market cap of $39.83 million, a PE ratio of -0.66 and a beta of -0.80. The company’s 50 day simple moving average is $1.01 and its 200-day simple moving average is $1.12. Barinthus Biotherapeutics has a 12-month low of $0.80 and a 12-month high of $4.16.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.01). The company had revenue of $14.97 million during the quarter. As a group, equities research analysts forecast that Barinthus Biotherapeutics will post -1.38 EPS for the current fiscal year.

Institutional Trading of Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. Gilead Sciences Inc. bought a new stake in Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics makes up approximately 0.0% of Gilead Sciences Inc.’s investment portfolio, making the stock its 14th largest position. Gilead Sciences Inc. owned about 1.54% of Barinthus Biotherapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.